Bradykinin

Pharvaris announces plans to initiate a clinical trial for deucrictibant in acquired angioedema, expanding beyond its ongoing Phase 3 trials in hereditary angioedema. The decision follows encouraging results in three patients, as the company advances its bradykinin B2 receptor antagonist program with both immediate and extended-release formulations.

Astria Therapeutics is initiating the ALPHA-ORBIT Phase 3 trial to evaluate navenibart for hereditary angioedema (HAE) with flexible dosing.

The European Commission and the MHRA have approved CSL's Andembry (garadacimab) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older.

Phase 2 trial results show NTLA-2002 significantly reduces swelling attacks in hereditary angioedema (HAE) patients, with up to 80% attack reduction at the 50 mg dose.